Long Ideas - We last covered Synageva BioPharma (GEVA) in early January, arguing that the company faced fundamental risks that made its valuation a concern moving forward. But … Continue Reading
Read NowMost Popular - Shares of TG Therapeutics (TGTX) had a rough end to last week and a worse beginning to this week. But it was that weakness that … Continue Reading
Read NowLong Ideas - Shares of TG Therapeutics (TGTX) have soared in 2013, rising nearly 80% year-to-date as investors caught wind of the company’s unique oncology assets and their … Continue Reading
Read NowMost Popular - The FDA accepted Durect’s (DRRX) New Drug Application for Posidur on Thursday, causing shares to gap up and continue higher through the day. Analysts expect … Continue Reading
Read NowLong Ideas - Shares of Medivation (MDVN) fell sharply on Monday June 17, closing down over 6% on news that Johnson & Johnson (JNJ) has acquired Aragon Pharmaceuticals … Continue Reading
Read NowMost Popular - Vascepa’s commercial prospects are one of the hottest topics of debate in biotechnology, and this week PropThink outlined why you can trade Amarin (AMRN) in … Continue Reading
Read NowLong Ideas - Although Infinity Pharmaceuticals’ (INFI) post-ASCO selloff, which we discussed on Monday, was perhaps the most prominent ASCO demolition, it wasn’t the only unwarranted decline. Shares … Continue Reading
Read Now